CardioMEMS in a Busy Cardiology Practice: Less than Optimal Implementation of a Valuable Tool to Reduce Heart Failure

Related Experiment Video

Updated: Feb 1, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Robby Singh1, Leon Varjabedian1, Georgy Kaspar1

  • 1Providence Hospital, Michigan State University, Detroit, MI, USA.

Cardiology Research and Practice
|December 8, 2018
PubMed

Insights

Despite proven benefits for heart failure patients and healthcare costs, the CardioMEMS device is underutilized. Physician and patient education are crucial to increase adoption of this technology for managing heart failure.

Area of Science:

  • Cardiology
  • Medical Devices
  • Health Economics

Background:

  • Congestive heart failure (CHF) is a major cause of illness and death, leading to high healthcare costs.
  • Remote pulmonary artery pressure monitoring with CardioMEMS can reduce heart failure hospital readmissions.
  • The CHAMPION trial demonstrated the efficacy of CardioMEMS in NYHA Class III heart failure patients.

Purpose of the Study:

  • To assess the real-world adoption rate of the CardioMEMS device in eligible heart failure patients.
  • To identify barriers to CardioMEMS implantation in a clinical setting.

Main Methods:

  • Retrospective review of electronic medical records for CHF patients.
  • Inclusion criteria based on CHAMPION trial eligibility and ACC/AHA guideline-directed medical therapy.
  • Analysis of CardioMEMS implantation rates among eligible patients.

Main Results:

  • Out of 473 CHF patients, 85 were eligible for CardioMEMS implantation.
  • Only 18 patients (21% of eligible, 4% of total cohort) received the device.
  • A significant gap exists between device eligibility and actual implantation.

Conclusions:

  • The adoption of CardioMEMS technology is poor despite its benefits.
  • 79% of eligible patients did not receive the CardioMEMS device.
  • Improved physician and patient education is necessary to increase CardioMEMS utilization for CHF management.
Abstract

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
933
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
888
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
339
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
968
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
316